tbuckley/cabot-search huggingface dataset:
HLA Ligandome Analysis in Multiple Myeloma Reveals Novel Naturally Presented Myeloma-Associated Antigens Showing Stable Expression Under Proteasome Inhibitor Therapy
Authors: Simon D. Walz, Daniel J. Kowalewski, Heiko Schuster, Katja Weisel, Helmut R. Salih, Lothar Kanz, Hans-Georg Rammensee, Stefan Stevanovic, Juliane S. Stickel
Journal: Blood (2014)
The Physician and Biologic Warfare
Authors: Dan Crozier
Journal: New England Journal of Medicine (1971)

Abstract The United States has discontinued all preparation for the offensive use of biologic weapons; this does not mean that this form of warfare might not be used against us. The most effective use of this weapon probably would be against heavily populated urban centers. For this reason medical management of civilian casualties may create greater problems than the care of military personnel. Although the military services must develop the concepts of defense against such an attack, it will be the responsibility of the civilian as well as the military physician to provide medical care. It is very possible that the first indication of an attack would be widespread illness in the target population. Immunoprophylactic measures would be helpful but are not the final answer. If the diagnosis and an etiologic identification can be established rapidly, information can be disseminated and a reasonable form of medical management can be provided.
Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis (vol 111, pg 763, 2003)
Authors: U Wahn, Eo Meltzer, Af Finn, Ml Kowalski, P Decosta, G Hedlin, P Scheinmann, Claus Bachert, Jer Pinto, C Baena-Cagnani, P Potter, Fer Simons, E Ruuth
Journal: Journal of Allergy and Clinical Immunology (2003)
Antibiotic perturbation of the murine gut microbiome enhances the adiposity, insulin resistance, and liver disease associated with high-fat diet
Authors: Douglas Mahana, Chad M. Trent, Zachary D. Kurtz, Nicholas A. Bokulich, Thomas Battaglia, Jennifer Chung, Christian L. Müller, Huilin Li, Richard A. Bonneau, Martin J. Blaser
Journal: Genome Medicine (2016)

Obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD) are serious health concerns, especially in Western populations. Antibiotic exposure and high-fat diet (HFD) are important and modifiable factors that may contribute to these diseases. To investigate the relationship of antibiotic exposure with microbiome perturbations in a murine model of growth promotion, C57BL/6 mice received lifelong sub-therapeutic antibiotic treatment (STAT), or not (control), and were fed HFD starting at 13 weeks. To characterize microbiota changes caused by STAT, the V4 region of the 16S rRNA gene was examined from collected fecal samples and analyzed. In this model, which included HFD, STAT mice developed increased weight and fat mass compared to controls. Although results in males and females were not identical, insulin resistance and NAFLD were more severe in the STAT mice. Fecal microbiota from STAT mice were distinct from controls. Compared with controls, STAT exposure led to early conserved diet-independent microbiota changes indicative of an immature microbial community. Key taxa were identified as STAT-specific and several were found to be predictive of disease. Inferred network models showed topological shifts concurrent with growth promotion and suggest the presence of keystone species. These studies form the basis for new models of type 2 diabetes and NAFLD that involve microbiome perturbation.
Abstract 695: Synergistic antitumor effects of polo like kinase inhibitor volasertib in combination with ionizing radiation in glioblastoma
Authors: Jianwen Dong, Nghi Nguyen, Ravesanker Ezhilarasan, Shaofang Wu, Yuji Piao, Soon Young Park, Ningyi Tiao, Clifford Stephan, Erik P. Sulman, John F. de Groot
Journal: Cancer Research (2015)

Abstract Despite the availability of hundreds of drugs, there is little data on the efficacy of these agents in the extremely heterogeneous populations of tumor cells observed in glioblastoma. In this study, a high-throughput compound-screening (HTS) assay was used to identify drug sensitivities of a panel of 15 glioblastoma stem cell (GSC) lines, which are representative of the classic the cancer genome atlas (TCGA) molecular subtypes, to 21 compounds in Published Protein Kinase Inhibitor Set (PKSI). This HTS screen identified sensitivity of GSCs to inhibition of polo like kinase-1 (PLK-1), a key regulator of mitosis. Given that PLK-1 is often overexpressed in a broad spectrum of cancers, and with highest expression levels being correlated with poor prognosis in several cancer types as well, we further verified the HTS result with the second-generation PLK1 inhibitor volasertib as a single agent or in combination with ionizing radiation in GSCs. Efficacy of volasertib was analyzed by Cell-Titer Glo 5 days after treatment. Morphological and molecular changes were approached by immunoblotting and flow cytometry after volasertib treatment, and in combination with ionizing radiation at 2 Gy. In vitro studies showed that volasertib inhibited cell viability with an IC50 ranging from 44.3nM to 4.36μM. Volasertib induced G2/M arrest accompanied by high levels of PLK-1, Aurora B and phosphor-histone 3 and prominent cleaved poly ADP ribose polymerase (PARP) in a dose- and time-dependent manner. Colony formation assay demonstrated that volasertib and ionizing radiation had synergistic effects on colony formation inhibition, suggesting that GSCs arrested in M phase by volasertib are more sensitive to ironizing radiation. The promising in vitro results of volasertib in GSCs led to further investigate the drug efficacy in intracranial xenograft models by volasertib alone, and in combination with radiation. Taken together, our results reinforce the potential therapeutic candidate of volasertib as a single agent and in combination with ionizing radiation in glioblastoma. Citation Format: Jianwen Dong, Nghi Nguyen, Ravesanker Ezhilarasan, Shaofang Wu, Yuji Piao, Soon Young Park, Ningyi Tiao, Clifford Stephan, Erik P. Sulman, John F. de Groot. Synergistic antitumor effects of polo like kinase inhibitor volasertib in combination with ionizing radiation in glioblastoma. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 695. doi:10.1158/1538-7445.AM2015-695
Signaling Through CD43 Induces Natural Killer Cell Activation, Chemokine Release, and PYK-2 Activation
Authors: Marta Nieto, José Luis Rodrı́guez-Fernández, Francisco Navarro, David Sancho, José M.R. Frade, Mario Mellado, Carlos Martı́nez-A, Carlos Cabañas, Francisco Sánchez-Madrid
Journal: Blood (1999)
Patient journey after admission for acute heart failure: length of stay, 30‐day readmission and 90‐day mortality
Authors: Beth A. Davison, Marco Metra, Stefanie Senger, Christopher Edwards, Olga Milo, Daniel M. Bloomfield, John G. Cleland, Howard C. Dittrich, Michael M. Givertz, Christopher M. O'Connor, Barry M. Massie, Piotr Ponikowski, John R. Teerlink, Adriaan A. Voors, Gad Cotter
Journal: European Journal of Heart Failure (2016)
Abstract 17784: The Genesips Project: an NHLBI-Sponsored induced Pluripotent Stem Cell (iPSC) Resource for the Study of Cardiovascular Diseases
Authors: Ivan Carcamo-Orive, Paige Cundiff, Hope Lancero, Mohammad Shahbazi, Fahim Abbasi, Sheena Abraham, Gerald Reaven, Sean Whalen, Sunita D’Souza, Gaurav Pandey, Achchhe Patel, Eric Schadt, Ihor Lemischka, Joshua Knowles, Thomas Quertermous
Journal: Circulation (2014)

The study of complex cardiovascular disease (CVD) has been hampered by the lack of appropriate human cellular model systems. In response, the NHBLI sponsored the NextGen Consortium, which encompasses 9 independent efforts spanning the portfolio of NHLBI related phenotypes. The goals of the consortium include: 1. To develop and improve methods for large-scale production and characterization of induced pluripotent stem cell (iPSC) models for CVD; 2. To create a resource of iPSC lines from a large number of phenotypically and genotypically characterized individuals. Our GENESiPS project is focused on insulin resistance (IR), a condition that affects 25-33% of the US population with serious health consequences including risk of type II diabetes and CVD. Although much is known about the physiological changes occurring during IR, little is known about the molecular pathways that drive the appearance of IR. Certain mature cell types as adipocytes, endothelial cells and skeletal muscle cells have been associated with the origin, maintenance and progression of IR. IPSCs offer an unprecedented opportunity of modeling human disease in vitro. We have created iPSC lines on insulin resistant and insulin sensitive patient groups with prior GWAS genotyping. Differentiation of these iPSCs to relevant cell types is providing the opportunity to correlate insulin sensitivity and high-density genetic variation data with specific cell-based profiling. We will validate our in vitro model and study the molecular pathways that define IR and its relationship to endothelial dysfunction. Relevant to the larger scientific community the establishment of iPSC lines on over 150 individuals (3 to 6 clones per patient) that reflect the range of insulin resistance in the general population. The iPSC lines were created from erythroblasts using the non-integrative Sendai virus system, passaged to allow clearance of Sendai virus and growth in feeder free conditions. The lines have been extensively characterized for markers of pluripotency (Tra1-60), sample identity and genomic integrity. Through the NextGen consortium, these lines, as well as phenotypic and genome-wide genotyping data will be available to qualified investigators.
Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis–Related Pulmonary Arterial Hypertension
Authors: Matthew R. Lammi, Stephen C. Mathai, Lesley Ann Saketkoo, Robyn T. Domsic, Christine Bojanowski, Daniel E. Furst, Virginia D. Steen
Journal: Arthritis & Rheumatology (2015)

To compare time to clinical worsening (TTCW) based on initial oral therapy for pulmonary arterial hypertension (PAH) in patients with systemic sclerosis (SSc)-related PAH.Using data from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) registry (a multicenter prospective observational study enrolling SSc patients with incident pulmonary hypertension), we selected patients with group 1 PAH (World Health Organization Clinical Classification system) who received initial therapy (for 6 months) with an endothelin receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, or a combination of these 2 agents (ERA/PDE5 inhibitor). The main outcome was TTCW, defined as the first occurrence of death, PAH-related hospitalization, lung transplantation, initiation of parenteral prostacyclin treatment, or worsening symptoms.Ninety-eight patients (24 in the ERA group, 59 in the PDE5 inhibitor group, and 15 in the ERA/PDE5 inhibitor group) were included. No significant differences in the baseline characteristics of the patients were observed. TTCW was significantly worse in patients in the ERA group compared with those in the PDE5 inhibitor group or the ERA/PDE5 inhibitor group. Ten patients (41.6%) in the ERA group died during the 3-year observation period, compared with 4 patients (6.8%) in the PDE5 inhibitor group and 1 patient (6.7%) in the ERA/PDE5 inhibitor group. Baseline factors that were independently associated with a shorter TTCW were initial treatment with an ERA (hazard ratio [HR] 2.63 [P = 0.009]), lower diffusing capacity for carbon monoxide (HR 0.69 per 10% of predicted change [P = 0.04]), and higher pulmonary vascular resistance (HR 1.10 per Wood unit change [P = 0.007]).Compared with initial treatment with a PDE5 inhibitor or combination therapy with an ERA and a PDE5 inhibitor, initial therapy with an ERA in patients with SSc-related PAH was associated with significantly worse TTCW, even after adjustment for commonly accepted prognostic factors. Further study into the optimal initial oral therapy for patients with SSc-related PAH is needed.
TCTAP C-128 Acute Brachial Artery Thrombosis Associated with Heparin-induced Thrombocytopenia After Transradial Coronary Intervention
Authors: Yisik Kim, Jei Keon Chae, Soo-Kyeong Song, Ji-Young Yoon, Laeyoung Jung, Sun-Hwa Lee, Sang-Rok Lee, Kyoung-Suk Rhee, Won-Ho Kim, Jae-Ki Ko
Journal: Journal of the American College of Cardiology (2016)
Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with <i>BRAF</i> V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).
Authors: David Planchard, Harry J.M. Groen, Tae Min Kim, James R. Rigas, Pierre Jean Souquet, Christina S. Baik, Fabrice Barlesi, Julien Mazières, Elisabeth A. Quoix, C. Martin Curtis, Bijoyesh Mookerjee, Arundathy N. Bartlett-Pandite, Christine Tucker, Anthony D'Amelio, Bruce E. Johnson
Journal: Journal of Clinical Oncology (2015)

8006 Background: In 78 BRAF V600E mut NSCLC pts, single agent D induced an overall response rate (ORR) of 32%. The combination of D and T (DT) has demonstrated significant improvements in efficacy compared with BRAFi monotherapy in BRAFV600 mut metastatic melanoma. Here, we report interim safety (33 pts) and efficacy (24 pts) data for NSCLC pts enrolled in this phase II DT study. Methods: This single-arm, 2-stage, phase II study was in advanced BRAFV600E mut NSCLC pts who failed at least 1 line of chemotherapy. D was dosed at 150 mg orally twice daily and T at 2 mg once daily. The primary endpoint was investigator-assessed ORR per RECIST 1.1 criteria. A minimum response rate ( ≥ 6 out of first 20 pts) was required to continue into the second stage. Results: Median age of 33 pts was 66 yrs (range 49–88 yrs). Most pts were female (64%), White (82%), former smokers (73%), and had adenocarcinoma (88%). Twenty-seven pts (82%) remain on therapy, and 6 have stopped (4 with disease progression, 2 due to adverse events [AEs]). Twenty-four pts were evaluable for efficacy (confirmed response). ORR was 63% (n = 15, partial responses; 95%CI 40.6%–81.2%), with responses being observed by the first scan (6 weeks) and disease control rate (DCR) for > 12 weeks was 88% (95% CI 67.6%–97.3%). Independent review response rates were consistent with investigator-assessed response. Most common ( > 20%) AEs were pyrexia, diarrhea, nausea, vomiting, decreased appetite, asthenia, cough, peripheral edema, and rash, mostly grade 1 or 2. Grade 3 AEs occurred in 39% of pts; most frequent were hyponatremia (6%), neutropenia (6%), and dehydration (6%). One pt (3%) had a grade 4 AE (hyponatremia) and 1 pt (3%) had a fatal serious AE of pleural effusion. AEs leading to a dose reduction were reported in 9 pts (27%). Cutaneous squamous-cell carcinoma and keratoacanthoma occurred in 2 pts (6%). Conclusions: DT in BRAF V600E mut advanced NSCLC pts shows early antitumor activity with an ORR of 63% and a manageable safety profile. The study met the criteria for progression to the second stage. Clinical trial information: NCT01336634.
High mortality during direct acting antiviral therapy for hepatitis C patients with Child’s C cirrhosis: Results of the Irish Early Access Programme
Authors: Emma Gray, Aisling O’Leary, Stephen Stewart, Colm Bergin, Mary Cannon, Garry Courtney, Orla Crosbie, Cillian F. De Gascun, Liam J. Fanning, Eoin Feeney, Diarmaid D. Houlihan, Barry Kelleher, Jack S. Lambert, John Lee, Patrick Mallon, Sam McConkey, Aiden McCormick, Susan McKiernan, Cora McNally, Frank Murray, Gary Sheehan, Suzanne Norris
Journal: Journal of Hepatology (2016)
P1169 : Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study
Authors: L. Fabris, A. Ciaccio, S. Okolicsanyi, M. Rota, P.A. Cortesi, M.R. Buonocore, M. Gemma, P. Giani, L.S. Belli, S. Fagiuoli, L. Scalone, M.G. Valsecchi, L.G. Mantovani, M. Strazzabosco
Journal: Journal of Hepatology (2015)
TCTAP A-117 Impact of Stent Diameter on Stent Patency After Self-Expanding Paclitaxel-Eluting Stent Implantation in the Superficial Femoral Artery: An Optical Frequency Domain Imaging Study
Authors: Kojiro Miki, Kenichi Fujii, Tetsuo Horimatsu, Tohru Masuyama, Masaharu Ishihara
Journal: Journal of the American College of Cardiology (2016)
Informing Patients: Translating the NCCN Guidelines
Authors: Joan S. McClure
Journal: Journal of the National Comprehensive Cancer Network (2011)

Health care professionals are accustomed to using clinical practice guidelines to elucidate questions regarding cancer and its treatment.In a recent survey by the Association of Community Cancer Centers, 94% of physicians indicated that they refer to clinical practice guidelines when engaged in direct patient care.Since 1996, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) have been recognized as an authoritative source of evidence-based recommendations for managing the vast majority of cancers.The NCCN Guidelines recommendations represent a distillation of up-to-date evidence evaluated by expert subspecialty clinicians organized into flow charts that follow the clinical decision-making process.Clinicians can go to the NCCN Guidelines to find out the current thinking of expert clinicians on a wide variety of issues and to find the information they need quickly and efficiently.For someone diagnosed with cancer, the landscape looks different.The world changes dramatically.A body that has served well for decades suddenly seems far less reliable, and survival itself may be in question.Information that was at most peripheral to daily concerns suddenly takes on tremendous importance.The vocabulary is unfamiliar, almost a foreign language to some patients.What type of cancer is it?What is a primary site?Is it really the same type of cancer when it has spread to the lungs or the bones?Decisions are needed regarding workup, primary therapy, and whether one treatment is better than the others.Decisions are also needed on where to be treated and by whom, and how to find a specialist and what kind, among many others.Patients are aware that some of these decisions might mean life or death, but, without knowledge and experience, they may not know which ones.It feels like an emergency.Surely there must be somewhere to get answers.
TCTAP A-048 Outcome of Everolimus Eluting Bioabsorbable Vascular Scaffold(BVS) Compared to Non BVS Drug Eluting Stent in the Management of ST-Segment Elevation Myocardial Infarction(STEMI) - A Comparative Study
Authors: Soumya Patra, Rabindranath Chakraborty, Praskas Chandra Mandal
Journal: Journal of the American College of Cardiology (2016)
Development and characterization of patient-derived xenografts to guide precision medicine in bladder cancer.
Authors: Chong-xian Pan, Hongyong Zhang, Tzu-yin Lin, Clifford Tepper, James Keck, Paramita Ghosh, Susan D. Airhart, Luis Carvajal-Carmona, Carol J. Bult, David R. Gandara, Edison T. Liu, Ralph de Vere White
Journal: Journal of Clinical Oncology (2015)

e15522 Background: The objective of this project was to establish a patient-derived bladder cancer xenograft (PDX) platform annotated with genomic and patient clinical information to guide precision medicine and develop targeted therapy in bladder cancer. Methods: PDXs were developed from direct implantation of patient bladder cancer specimens into immunodeficient NSG mice. Deep sequencing with computational biology was performed to molecularly characterize PDXs and to identify druggable genetic aberrations. NSG mice carrying PDXs were treated with matched targeted therapies to determine efficacy and study secondary resistance mechanisms through serial biopsies. Results: Twenty-two PDXs with annotated clinical information were established. PDXs preserve the morphological features and 92–97% of genetic aberrations of the original bladder cancer specimens. For drug re-purposing, an EGFR/HER2 dual inhibitor lapatinib was effective in PDX BL0440 (progression-free survival or PFS of 25.4 days versus 18.4 days in the control, p = 0.007), but not in PDX BL0269 (12 days versus 13 days, p = 0.16) although both expressed HER2. To screen for the most effective therapy, we evaluated three drugs matched with genetic aberrations in PDX BL0269; but only a PIK3CA inhibitor BEZ235 was effective (PFS over 3 weeks vs 11 days, p < 0.0001). To study the mechanisms of secondary resistance, a fibroblast growth factor receptor 3 inhibitor BGJ398 prolonged PFS of PDX BL0293 from 9.5 days of the control to 18.5 days (p < 0.0001), and serial biopsies revealed that the MAPK/ERK and PIK3CA-AKT pathways were activated upon resistance. Inhibition of these pathways significantly prolonged PFS from 12 day of the control to 22 days (p = 0.001). To screen for effective chemotherapy, 4of the first 6 PDXs were sensitive to the cisplatin/gemcitabine combination, and chemoresistance to one drug could be overcome by the other drug. Conclusions: The PDX platform allows the simultaneous screening for multiple targeted therapies, chemotherapy, or combinations for the most efficacious drugs or combination, serial biopsies during treatment to study drug resistance and for drug development, a task not possibly replicable at the clinical setting.
Nitrosamine Formation in Human Saliva2
Authors: Steven R. Tannenbaum, Michael C. Archer, John S. Wishnok, Walter W. Bishop
Journal: JNCI Journal of the National Cancer Institute (1978)

Journal Article Nitrosamine Formation in Human Saliva Get access Steven R. Tannenbaum, Steven R. Tannenbaum Search for other works by this author on: Oxford Academic PubMed Google Scholar Michael C. Archer, Michael C. Archer Search for other works by this author on: Oxford Academic PubMed Google Scholar John S. Wishnok, John S. Wishnok Search for other works by this author on: Oxford Academic PubMed Google Scholar Walter W. Bishop Walter W. Bishop Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 60, Issue 2, February 1978, Pages 251–253, https://doi.org/10.1093/jnci/60.2.251 Published: 01 February 1978 Article history Received: 25 March 1977 Accepted: 22 September 1977 Published: 01 February 1978
Co-Existent Primary Carcinoma of the Fallopian Tube and of the Breast
Authors: John F. Curran, Edward A. Kilroy
Journal: New England Journal of Medicine (1947)

THE purpose of this paper is to discuss primary carcinoma of the fallopian tube, and to submit a report of the first case at the Worcester City Hospital of carcinoma of the fallopian tube and carcinoma of the breast in the same patient. As in the vast majority of cases reported in the literature, the diagnosis of tubal carcinoma was not made preoperatively. It was only suspected during the operation for another pelvic disorder and was confirmed by routine pathological study of the tissues removed during the operation.Since Rokitansky's original pathological description in 1861 and the first accredited case . . .
A neonate with dyspnoea
Authors: Yong-Hai Zhou, Ming-Hua Zheng
Journal: BMJ (2016)

A newborn boy presented to the neonatal intensive care unit with dyspnoea at birth. He was born at 40+1 weeks’ gestation and weighed 2950 g, with Apgar scores of 9 at one minute and 9 at five minutes. On examination, his left lung breath sounds were absent and bowel sounds could be auscultated in the left thoracic cage. His respiratory rate was 70 breaths/min and there were no other …